A

Agilent manufactures analytical instruments and consumables that pharmaceutical companies, academic labs, and government agencies use to test everything from drug compounds to environmental samples. The company owns dominant market positions in liquid chromatography and mass spectrometry, creating sticky customer relationships through high-margin consumables that generate 40% of total revenue. Management expects the pharma end market to accelerate through 2025 as biotech funding recovers and new drug development pipelines expand. Trading at 18x forward earnings despite posting double-digit margins, Agilent offers exposure to the structural growth in life sciences R&D spending without the binary risks of drug development.